Clene cleared for accelerated NDA submission after successful FDA meeting

Clene (NASDAQ:CLNN) reported its first-quarter 2026 financial results on Thursday, highlighting a critical regulatory breakthrough that establishes a clear, accelerated path toward commercialization for its investigational ALS drug, CNM-Au8.

Clene announced that final minutes from its recent Type C meeting with the FDA confirmed the agency believes the company's existing data may support a New Drug Application (NDA) for CNM-Au8 under the Subpart H accelerated approval pathway.

Crucially, the FDA indicated that reductions in Neurofilament Light Chain (NfL)—a prominent biomarker for nerve cell damage—could serve as a reasonably likely surrogate endpoint to predict clinical benefit in patients with amyotrophic lateral sclerosis (ALS).

Following this definitive regulatory guidance, Clene has finalized its submission timeline, targeting the formal NDA filing for the third quarter of 2026.

To satisfy the FDA's requirement for a confirmatory clinical trial under the accelerated framework, the company has scheduled the initiation of its Phase 3 RESTORE-ALS study for the first quarter of 2027.

Financially, Clene reported a net loss of $8.1 million, or $0.69 per share, for the quarter ended March 31, 2026.

The company successfully executed a disciplined cost-reduction strategy, sharply lowering its core research, development, and administrative expenses compared to the previous year.

The bottom line, however, reflected a $6 million non-cash charge primarily driven by warrant-related accounting and interest expenses on its expanded debt facility.

To extend its operational runway through these vital regulatory gates, Clene completed a series of strategic financings.

Following an oversubscribed $28 million registered direct offering in January, the company closed an additional $7 million underwritten equity offering on May 6.

Furthermore, Clene successfully amended its $10 million senior secured convertible notes, deferring all monthly principal and interest payments and extending the maturity date out to August 2027.

Clene concluded the first quarter with $5.9 million in cash and cash equivalents.

Factoring in the gross proceeds from the May equity raise and the near-term cash preservation from the debt amendment, management projects its current cash runway will extend well into the fourth quarter of 2026, and potentially into 2027, assuming the execution of outstanding Series A warrants upon NDA acceptance.